Allergy Therapeutics announces FDA clearance of IND application for novel peanut allergy vaccine candidate VLP Peanut

• Paves the way for start of VLP Peanut vaccine candidate’s Phase I PROTECT trial in H1 2022
• Topline data from first-in-human trial expected in H1 2023
• Analysis of data from earlier ex-vivo biomarker study, VLP001, demonstrates beneficial mode of action of the vaccine candidate

Full details:

https://ir.q4europe.com/solutions/allergytherapeutics2018tf/3856/newsArticle.aspx?storyid=15315077